Market Overview

Vizient, Inc. Urges CMS to Reconsider 340B & "Site-Neutral" Policies in Proposed OPPS Rule

Share:

Vizient,
Inc
. is disappointed with the recently released Centers for Medicare
and Medicaid Services (CMS) annual outpatient prospective payment system
(OPPS) proposed rule, specifically those policies related to the 340B
Drug Pricing Program and "site-neutral" payments.

The 340B Program is critical to America's safety net, allowing hospitals
to provide lifesaving programs to the nation's most vulnerable patients
and communities. CMS is proposing to deepen last year's damaging cuts to
340B hospitals by extending them to an even greater number of hospital
outpatient clinics. This policy will not serve to lower the cost of
prescription drugs, but instead will only decrease access to care for
the nation's most vulnerable populations.

CMS has also proposed to continue harmful "site-neutral" payment cuts.
These payment reductions will further reduce access to hospital-level
outpatient care, especially in areas with already limited sources of
health care. Patients across the nation rely on outpatient services
provided by our member hospitals.

We urge CMS to reconsider both of these harmful proposals that only
serve to negatively impact hospitals' ability to provide high quality
health care services and impede access to care.

Vizient is the nation's largest health care performance improvement
company serving a diverse membership that includes academic medical
centers, pediatric facilities, community hospitals, integrated health
care delivery networks and non-acute health care providers.

About Vizient, Inc.

Vizient, Inc., the largest member-driven health care performance
improvement company in the country, provides innovative data-driven
solutions, expertise and collaborative opportunities that lead to
improved patient outcomes and lower costs. Vizient's diverse membership
base includes academic medical centers, pediatric facilities, community
hospitals, integrated health delivery networks and non-acute health care
providers and represents approximately $100 billion in annual purchasing
volume. The Vizient brand identity represents the integration of VHA
Inc., University HealthSystem Consortium and Novation, which combined in
2015, as well as MedAssets' Spend and Clinical Resource Management (SCM)
segment, including Sg2, which was acquired in 2016. In 2018, Vizient
again received a World's Most Ethical Company designation from the
Ethisphere Institute. Vizient's headquarters are in Irving, Texas, with
locations in Chicago and other cities across the United States. Please
visit www.vizientinc.com
as well as our newsroom,
blog,
Twitter,
LinkedIn
and YouTube
pages for more information about the company.

View Comments and Join the Discussion!